CHMP refuses to recommend Sanofi-Pasteur's pandemic flu vaccine in EU
This article was originally published in Scrip
Executive Summary
The EU's CHMP has decided not support the marketing authorisation application for Sanofi-Pasteur's pandemic inactivated H5N1 influenza vaccine, Emerflu, because it believes that its immunogenicity is too low to illicit an adequate antibody response.